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Abstract:  Cyclooxygenase  (COX)  expression  in  the  brain  is  associated  with  pro-inflammatory  activities,  which  are  
instrumental in neurodegenerative processes such as Parkinson’s disease (PD). It is discussed that drugs with the capacity 
to rescue dopaminergic neurons from microglia toxicity and neuroinflammatory processes may result in an amelioration 
of parkinsonian symptoms by delaying the onset or slowing progression. This article reviews the involvement of COX in 
neuroinflammation, specifically focussing at the role of selective COX-2 inhibition in neuroinflammation and neurode-
generation in Parkinson’s disease. 
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INTRODUCTION 
  Parkinson’s  disease  (PD)  is  one  of  the  most  common 
neurodegenerative diseases, and is characterised by the pro-
gressive loss of dopaminergic and other catecholaminergic 
neurons and projections from brain stem regions [11]. Re-
search on the aetiology of PD has resulted in an abundance 
of information on neurodegenerative processes, but still little 
is known about the events causing the initiation and also the 
progression of the disease. PD neurodegeneration was previ-
ously considered to be a purely neuronal process, but is now 
seen as the result of multiple pathogenic factors. In recent 
years, the cross talk between neurons and glia has become an 
intensive  research  focus  for  the  understanding  of  brain 
pathophysiology.  More  specifically,  neuroinflammatory 
processes  involving  an  increased  expression  of  cyclooxy-
genase (COX) and elevated prostaglandin E2 (PGE2) levels 
have  been  associated  with  several  neurodegenerative  dis-
eases, such as PD, Alzheimer’s disease (AD) and amyotro-
phic lateral sclerosis (ALS) [39]. 
  COX comes in  two isoforms: COX-1, which is widely 
distributed in virtually all cell types and is thought to medi-
ate physiological responses, and COX-2, an inducible form. 
COX-2 is rapidly expressed in several cell types in response 
to  cytokines,  growth  factors  and  pro-inflammatory  mole-
cules. COX-2 has emerged as the isoform primarily respon-
sible for prostanoid production in acute and chronic inflam-
matory conditions. Thus, COX-2 may contribute to neurode-
generative processes. However, in spite of intense research 
in the last decade, the evidence for a direct role of COX-2 in 
neurodegenerative  disease  and  neuroprotective  effect  of 
COX-2 inhibition is still controversial. This article will re-
view the role of COX-2 in neurodegenerative diseases with 
the main focus on its possible roles in PD progression. 
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COX IN PD: EPIDEMIOLOGICAL STUDIES 
  The hypothesis that neuroinflammation is a key compo-
nent in the progression of Parkinson’s disease, has been cor-
roborated by several epidemiological studies. To date, nine 
epidemiological  studies  have  investigated  the  association 
between regular NSAID use and risk of PD. The conven-
tional  NSAID  ibuprofen  has  the  strongest  epidemiological 
support for risk reduction of PD development [16, 17]. In the 
first study, more than 44000 men and nearly 99000 women 
were followed for 14 and 18 years, respectively. A total of 
236 men and 179 women developed PD. The risk of devel-
oping  PD  was  45  %  lower  among  regular  users  of  non-
aspirin NSAIDs and in those who took two or more tablets 
of aspirin a day [17]. In a subsequent study with a cohort of 
146565 people, ibuprofen was associated with 35 % lower 
risk of PD. There was a significant trend for lower risk with 
increasing consumption of ibuprofen (from relative risk (RR) 
0.73 with fewer than 2 tablets per week to RR 0.61 for daily 
use) [16]. No associations were found for aspirin or other 
NSAIDs, although it should be noted that most people in the 
cohort  used  ibuprofen.  More  recently,  a  population-based 
study in 293 PD cases and 286 controls showed protective 
effect  for  aspirin  users  only  in  women  (OR  0,51)  and  a 
stronger effect for non-aspirin NSAID users without gender 
difference, particularly for those who reported more than two 
years of use (OR 0,44) [59]. 
  However, in other studies findings were controversial. A 
case-control  study  in  1258  PD  patients  and  6638  controls 
reported that non-aspirin NSAID use reduced PD risk only in 
men  but  surprisingly  did  the  opposite  in  women.  Use  of 
NSAIDs was associated with a 20 % reduction of PD devel-
opment  in  men  and  a  20  %  increase  in  women  [29].  A 
smaller study in 392 subjects found that PD cases less fre-
quently used NSAIDs than controls, however this difference 
did not reach significance. They also showed a significant 
association  between  pre-existing  immune-related  diseases 
and development of PD,  especially  in women [10], which 
may support the hypothesis of an inflammatory component 
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PD  patients  and  383  controls,  however,  provided  limited 
support for the hypothesis of PD risk reduction by aspirin, 
and  no  indication  of  protection  by  other  NSAIDs  [55].  A 
family-based case control study in 356 PD patients and 317 
family controls revealed inverse associations of smoking and 
caffeine consumption with PD, but not of NSAID use [28]. 
Another  group  that  conducted  a  nested  case-control  study 
using  an  anti-hypertensive  agent  drug  database  found  no 
protective effect of past NSAID users and  even  a slightly 
higher risk of developing PD in current NSAID users (RR 
1,49)  [25].  Recently,  in  a  large  cohort  study  assessing 
697.078 subjects these authors did not find decreased risk for 
PD development with NSAID use [24]. Limitations of these 
studies  were  the  inability  to  assess  the  use  of  over-the-
counter NSAIDs and inability to  adjust for other potential 
PD risk factors as confounders. 
  Notably, the subjects in these studies used non-selective 
COX inhibitors. In the study of Chen et al, the non-selective 
COX  inhibitor  ibuprofen  showed  the  strongest  effect  in 
comparison  with  the  COX-1  inhibitor  aspirin.  However, 
most subjects in that study used ibuprofen. Selective COX-2 
inhibitors have only recently been introduced and are mostly 
used  as  second  choice  after  the  traditional  non-selective 
NSAIDs. Until now, no study has been performed to investi-
gate the influence of selective COX-2 inhibition on PD inci-
dence or PD progression. 
COX-1 AND COX-2 IN THE BRAIN 
  COX, also known as prostaglandin (PG) H synthase, ca-
talyses the first step in the synthesis of prostanoids from ara-
chidonic acid (AA). COX exhibits two catalytic activities: a 
bis-oxygenase  activity  (cyclooxygenase),  which  catalyses 
PGG2 formation from AA, and a peroxidase activity, which 
reduces PGG2 to PGH2. The peroxidase activity also results 
in the production of free radicals. Through the intermediate 
of  PGH2,  COX  enzymes  produce  5  prostanoids:  PGE2, 
PGF2,  PGD2,  PGI2  (prostacyclin)  and  thromboxane  A2 
(TxA2). PGs play a pivotal role in the biochemical mecha-
nisms that induce pain, hyperpyrexia, inflammatory cytopro-
tective  and  cytotoxic  processes.  Finally,  during  the  cy-
clooxygenase  activity,  COX  undergoes  a  conformational 
rearrangement  leading  to  an  unstable  intermediate.  This 
process is called “suicide inactivation” and it limits prosta-
noids synthesis [49]. 
  In the majority of tissues, COX-1 appears to be the only 
isoform  constitutively  expressed,  confirming  its  role  in 
physiological  functions  through  homeostatic  PG  synthesis. 
However, in brain, testes and kidney cells, both COX-1 and 
COX-2 were found to be expressed under physiological con-
ditions [49]. In rat brain, COX-1 and COX-2 expression is 
present in distinct areas of cerebral cortex and in hippocam-
pus.  In  the  midbrain,  pons  and  medulla,  COX-1  prevails 
[12]. Also in several regions of the human brain both COX-1 
and COX-2 expression are present, with COX-2 expression 
being  most  prominent  in  the  hippocampus  [63].  Recently, 
also a third variant of COX, named COX-3 has been identi-
fied [15]. COX-3 is a product of the COX-1 gene and has the 
expression  in  the  brain,  mainly  in  the  cerebral  cortex.  As 
COX-1, COX-3 is not induced by acute inflammatory stimu-
lation [46]. Enzymatic activity of COX-3 is glycosylation-
dependent and especially sensitive to the inhibitory activity 
of acetaminophen (paracetamol) [15]. COX-3 may represent 
the brain-specific COX isoform, explaining the potent anal-
getic  and antipyretic actions of paracetamol  in spite of its 
poor ability to inhibit COX in peripheral tissues. However, 
its functional role in the brain is largely unknown. 
  The potential role of COX isoforms in brain pathological 
conditions has been extensively reviewed in the past years. 
Only COX-2 is dramatically up-regulated during inflamma-
tory processes, which led to the concept that selective COX-
2 inhibition can reduce inflammation without affecting the 
physiological functions of COX-1. On the other hand, it has 
recently  been  brought  forward  that  COX-1  could  be  the 
mayor player in neuroinflammation by being predominantly 
localised in microglia and thus secrete PGs in response to 
microglia  activation.  COX-2,  which  is  mainly  localised  in 
neurons, is expected to increase PG synthesis in response to 
neuronal  insults  [18].  Consistent  with  a  suggested  role  of 
COX-2 in excitotoxic neuronal injury, COX-2 is expressed 
in  the  postsynaptic  neuronal  cell  bodies  of  glutamatergic 
synapses [34]. 
  Potential harmful downstream effectors of COX-2 toxic-
ity are PGE2 and free radicals. PGE2 has an enhancing effect 
on glutamate release, leading to neurotoxic levels of gluta-
mate.  COX-2  could  also  contribute  to  oxidative  stress-
mediated  damage  by  producing  oxidizing  reactive  species 
during  the  peroxidase  activity.  However,  the  beneficial  or 
detrimental role of COX-2 in inflammatory and neurodegen-
erative processes is still controversial. Several studies sug-
gest a special role for COX-2 in normal neural synaptic func-
tion.  The  “constitutive”  cerebral  COX-2  expression  is  de-
pendent on normal synaptic activity and is dynamically regu-
lated with rapid increases during seizures or ischemia, while 
down-regulation  occurred  by  glucocorticoids  [62].  COX-2 
immunoreactivity  is  seen  in  distal  dentrites  and  dendritic 
spines,  localized  to  excitatory  glutamatergic  neurons,  sup-
porting the role of COX-2 in synaptic activity. Furthermore, 
COX-2 inhibition with celecoxib impaired spatial memory in 
rats in an experiment using the Morris water maze, a hippo-
campal-dependent learning task [52]. Also ibuprofen, a non-
selective COX-inhibitor, caused memory consolidation defi-
cits in this experimental setting, which was associated with 
decreased expression of brain-derived growth factor (BDNF) 
[47].  COX-2  derived  PGE2  could  participate  in  synaptic 
plasticity  through  modulation  of  adrenergic,  noradrenergic 
and  glutamatergic  neurotransmission  and  regulation  of 
membrane excitability. Moreover, PGE2 is involved in the 
coupling of synaptic plasticity with cerebral blood flow, re-
sulting in a hyperaemic response [42].  
  In  experimental  models  with  neuronal  insults,  such  as 
ischemia,  COX-2  inhibition  provides  protection  from  neu-
ronal damage in the early phase of damage, without attenuat-
ing inflammatory gene expression [36]. In contrast,  in ex-
perimental  models  of  primary  neuroinflammation,  such  as 
lipopolysaccharide (LPS), detrimental effect of COX-2 inhi-
bition is seen with increased glial activation and inflamma-
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properties of COX-2, which have been coupled to the pro-
duction of specific prostaglandin metabolites by COX-2, the 
cyclopentanone prostaglandins [61], which are ligands of the 
peroxisome  proliferator-activated  receptor-γ  (PPAR-γ). 
However,  in  neurons,  cyclopentanone  prostaglandins  were 
reported to induce apoptosis [44]. Thus, in neurodegenera-
tive processes COX-2 could play a role in triggering neural 
cell death via its production of cyclopentanone prostagland-
ins. 
  In clinical trials that assessed long-term safety, selective 
COX-2  inhibitors  were  associated  with  cardiovascular  ad-
verse events. The VIGOR study reported a higher incidence 
of myocardial infarction in arthritis patients using rofecoxib 
compared  to  naproxen  (0,4  vs  0,1  %)  [7].  Retrospective 
analysis revealed that 35 % of these infarctions occurred in 
the 4 % of patients who in retrospect had been candidates for 
low-dose aspirin. It should also be noted that cardiovascular 
morbidity  is  increased  in  autoimmune  diseases,  especially 
rheumatoid arthritis. In the CLASS study, the incidence of 
cardiovascular  events  in the  celecoxib group was equal to 
that  in  the  classic  NSAID  group  [48].  A  meta-analysis  of 
clinical literature on COX-2 inhibitors concluded that cele-
coxib is the safest COX-2 inhibitor relating to the cardiovas-
cular safety data [33]. 
  Thus, potential differential effects of COX-2 inhibition in 
neurodegenerative processes need to be considered to differ-
entiate  neuroprotective  mechanisms  from  possibly  harmful 
effects. Below, we will specifically focus on the evidence of 
COX-2 involvement in experimental PD models. 
COX-2 IN PARKINSON’S DISEASE 
  Human and animal studies have shown robust microglia 
activation in PD, suggesting an important role of these cells 
in the pathogenesis of PD. On the contrary, astrogliosis has 
been  sporadically  observed  [41].  Interaction  of  microglial 
cells with apoptotic neurons has been reported to selectively 
promote COX-2 expression and PGE2 synthesis [20]. COX-
2 may mediate microglial activation and may play a key role 
in amplifying the inflammatory response with toxic effects. 
COX-2 may contribute to the progression of neurodegenera-
tion through the production of toxic free radicals and increas-
ing local glutamate concentration to toxic levels [6].  
  Interestingly, the healthy substantia nigra (SN) exhibits 
the  highest  concentration  of  microglia  in  the  brain,  which 
increases  with  age  [5].  Besides  being  prone  to  deleterious 
effects from oxidant stress by the high glutathione and iron 
concentrations in dopaminergic neurons [32], the SN is thus 
also  sensitive  to  neuroinflammation.  In  post-mortem  PD 
brains, the SN showed a high amount of activated microglia 
[38], suggesting involvement of these cells in the neurode-
generative process. Activated microglia are recruited to the 
SN and stuck to dopaminergic neurons. Once activated, glial 
cells  become  phagocytes  that  ingest  degenerating  neurons. 
This process occurs early in neurodegeneration and starts at 
the extending fibres, such as the dendrites [51]. Hence, det-
rimental  compounds  are  released  in  this  process,  such  as 
interleukin  (IL)-1β,  IL-6,  tumor  necrosis  factor-α  (TNF-α) 
and interferon-γ (IFN-γ), which may stimulate inducible ni-
tric oxide synthase (iNOS) or activate receptors involved in 
apoptosis [54]. Another pathway that links inflammation and 
cell death  involves NF-κB, which is known for its role in 
preventing apoptotic cell death. In a chronic MPTP model of 
PD, activation of NF-κB was revealed [22]. The synthesis of 
COX-2 is promoted by NF-κB as well as pro-inflammatory 
cytokines such as TNF-α, or via the c-Jun N-terminal kinase 
(JNK) pathway [53]. 
  Increased susceptibility to excitotoxicity in COX-2 over-
expressing neurons and neuroprotection by COX-2 inhibition 
has  been  shown  in  several  experimental  PD  models  [39]. 
Furthermore, the specific involvement of COX-2 in PD neu-
rodegeneration is supported by the observation that  MPTP 
neurodegeneration was mitigated in COX-2 knock out, but 
not in COX-1 knock out mice [26].  
  Increased microglial COX-2 expression was reported in 
post-mortem SN from 11 PD patients, whereas neuronal and 
astroglial COX-2 expression did not differ between PD pa-
tients  and control  subjects. It was  also seen that moderate 
COX-1 reactivity in neuronal somata and in few glial cells 
was similar in PD and control subjects [35]. However, an-
other study showed COX-2 to be specifically induced in do-
paminergic neurons in the SN in post-mortem PD subjects 
and  in  the  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) mouse model, whereas no obvious staining of astro-
cytes or activated microglia was detected [53]. On the other 
hand, in a 6-hydroxydopamine (6-OHDA) PD model study, 
celecoxib was shown to mitigate 6-OHDA induced micro-
glial activation [45]. A recent study claims that the COX-2 
specific NSAID valdecoxib also significantly mitigated mi-
croglial activation in a MPTP mouse model [57].  
  An explanation for the different findings of neuroprotec-
tive effect in several studies of neuroinflammation and neu-
rodegeneration may be in the timing of treatment. In most 
toxic  PD  model  studies,  anti-inflammatory  treatment  is 
started before or at the time of toxic lesion, which may be 
important to diminish early damaging reactions. This idea is 
supported  by  a  study  of  Shriram  et  al.,  showing  that 
minocycline  treatment  after  MPTP  lesion  attenuated 
microglial  activation,  but  failed  to  afford  neuroprotection 
[50].  Their  findings  suggest  that  attenuation  of  microglial 
activation  may  be  insufficient  to  modulate  neurotoxicity 
when transient activation of microglia may suffice to initiate 
neurodegeneration.  
  On the other hand,  microglia  independent neuroprotec-
tive effects of COX-2 inhibition have been reported. Cele-
coxib was recently shown to have an attenuating effect on 
LPS induced nigrostriatal neurodegeneration without affect-
ing microglial activation [30]. Also other studies suggest that 
the effect of COX-2 modulation may be independent from 
microglia activity. A study with 6-OHDA exposed neuronal 
cultures showed 2-fold higher prostaglandin (PG) levels, and 
prevention of PG increase by ibuprofen was inversely corre-
lated to dopaminergic cell loss. Thus the rise in PG levels 
with 6-OHDA exposure was not due to microglial activation 
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showed that MPTP increased PG in mixed neuron-microglia 
cultures, but not in neuron -, microglia -, or astroglia alone 
cultures, pointing at the importance of interaction between 
neurons and glial cells. PG increase was abolished by treat-
ment with DuP697, a COX-2 selective inhibitor, which also 
reduced  dopaminergic  neurotoxicity  [60].  Microglia-
independent  effect  of  COX  modulation  on  neuronal  cell 
death has also been suggested in an in vivo MPTP model. 
The  selective  COX-2  inhibitor  rofecoxib  blocked  ventral 
midbrain PG production in MPTP injected mice and attenu-
ated neuron and fiber loss, demonstrating the crucial enzy-
matic function of COX-2 to its neurotoxic effects on dopa-
minergic neurons. This report suggested that the neuropro-
tective effect of COX-2 inhibition was related to the block-
ade of COX-2-mediated dopamine oxidation and not to de-
creased microglial activation [53]. Moreover, a recent study 
showed that COX-2 facilitated dopamine oxidation in a cell-
free system and in COX-2 overexpressing SH-SY5Y cells, 
which was blocked by the COX-2 inhibitor meloxicam. This 
was accompanied by accumulation of α-synuclein oligomers, 
which is an early step in PD pathogenesis [14]. These find-
ings  suggest  that  increased  COX-2  in  dopaminergic  cells 
under stressful conditions can facilitate dopamine oxidation 
to  quinone  species,  triggering  oxidative  stress,  and  that 
COX-2 overexpression in dopaminergic cells may also play 
a role in α-synuclein accumulation. 
  In addition to these studies, we have recently performed a 
study with celecoxib treatment started after 6-OHDA striatal 
lesion in rats, and could not confirm a diminishing effect on 
microglia activation (submitted data). The aim of that study 
was  to  diminish  neuroinflammation  by  COX-2  inhibition, 
and  thereby  improve  blood-brain  barrier  (BBB)  P-
glycoprotein  (P-gp)  efflux  function.  However,  this  study 
showed decreased P-gp up-regulation after COX-2 inhibition 
by celecoxib. BBB P-gp efflux function is thought to play a 
role in the detoxification of the brain in several neurodegen-
erative diseases [3, 58]. This adverse effect of COX-2 inhibi-
tion,  which  is  also  described  in  epilepsy  models  [4],  may 
hamper the neuroprotective potential of COX-2 inhibition in 
neurodegenerative  disease.  Another  in  vivo  study  in  rats, 
however, did not show a substantial effect of celecoxib on P-
gp mediated efflux [21]. The discrepant findings relating to 
microglia  involvement  remain  to  be  reconciled;  however, 
several  studies  indicate  that  microglia-independent  actions  
of COX-2 could play key roles in PD neurodegeneration (see 
also Fig. (1). Microglia and COX involvement in neuronal 
injury).  
  It should also be borne in mind that interactions between 
apoptotic neurons and microglia can also lead microglia to 
acquire an anti-inflammatory phenotype with potential neu-
roprotective properties. Minghetti’s group has provided evi-
dence  that  under  chronic  stimulation  a  progressive  down-
regulation of glial pro-inflammatory molecule expression is 
seen,  while  the  synthesis  of  other  products  with  potential 
protective activities is stimulated [40]. Furthermore, relating 
to COX-2 activity, it has been found that genetic deletion of 
the PGE2 receptor exacerbated neuronal damage, suggesting 
a potential protective effect of PGE2 receptor activity [37]. 
Finally, it has been demonstrated that COX-2 induction in 
inflammation is expressed chronically and is also observed 
during the resolution of inflammation and during healing of 
wounds  [19].  In  chronic  inflammation,  COX-2  inhibition 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Microglia and COX involvement in neuronal injury. Various stimuli can activate microglia in Parkinson’s disease, including aggre-
gated α-synuclein, toxins (such as MPTP, 6-OHDA, LPS, rotenone, paraquat, pesticides). Intracellular signalling cascades involving NF-κB 
and MAP kinases lead to microglial activation and induction of proinflammatory mediators, including iNOS, NADPH oxidase and COX-2, 
and the subsequent release of cytokines (e.g. IL-1β, IL-6, TNF-α), nitric oxide (NO) and prostaglandins (including PGE2). COX-1 is consti-
tutively expressed on microglia and may be the primary source of PGE2 release in early inflammation phases. COX-2 is localized in neurons 
and contributes to PGE synthesis in response to neuronal insults. Astrocyte activation may increase glutamate levels with cytokine and COX-
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may  lead  to  exacerbation  of  inflammation  [1].  Thus,  it  is 
important  to  determine  whether  COX-2  inhibition  in  a 
chronic neuroinflammatory process will attenuate inflamma-
tion or might have differential effects. 
CONCLUDING REMARKS 
  When these experimental findings have to be translated 
to  the  human  disease,  questions  that  remain  are  whether 
COX-2 inhibition could be effective to decrease PD risk and 
progression, or whether indeed undesired effects can be seen 
relating to inhibition of inflammatory processes in neurode-
generation. It needs to be further investigated whether mi-
croglia activation is involved in disease progression in PD 
patients. In vivo PET imaging studies have shown increased 
microglia activation in PD patients; however its relation to 
disease  progression  is  still  unclear  [27,  43].  Furthermore, 
these methods are so far  insufficient to quantify microglia 
activation and measure a possible effect of anti-inflammatory 
treatment in patients [2]. New PET tracers for quantification 
of microglia  activation are being developed for use in pa-
tients [8, 9, 23, 31, 56] and may help to further elucidate 
these  issues  in  the  human  disease  situation.  On  the  other 
hand,  COX-1  is  predominantly  localized  in  microglia  and 
could be a mayor player in the glial inflammatory response. 
The epidemiological evidence may point at a decreased risk 
of PD development by non-selective NSAID use rather than 
decreased progression of the disease. However, the potential 
protective  effect  of  COX-1  inhibition  as  well  as  COX-
independent effects of several NSAIDs  in PD needs to be 
further investigated.  
  Local  inflammatory  reactions  of  the  human  brain  may 
persist for much longer than in experimental rodent models. 
As  a  consequence,  this  may  lengthen  the  release  of  toxic 
substances subsequent to the acute inflammatory response. It 
is hypothesised that a harmful substance first induces reac-
tive microgliosis and secretion of its pro-inflammatory fac-
tors, such as PGE2 and cytokines. These may enhance COX-
2 dopaminergic neuronal activity and lead to a progressive 
wave of neuronal damage, and so on. As COX-1 is mainly 
expressed on microglia, early damage of an insult to the SN 
may be diminished mainly by COX-1 inhibition to decrease 
reactive  microgliosis.  COX-2  inhibition  is  hypothesised  to 
diminish  neuronal  damage  through  microglia-independent 
mechanisms such as COX-2 mediated dopamine oxidation. 
However, the potential of exacerbation of a chronic inflam-
matory reaction by COX-2 inhibition in the human disease 
situation warrants further research, which could be aided by 
in vivo PET imaging in rodent models as well as patients. 
Furthermore, the possible side effect of COX-2 inhibitors of 
inhibiting brain protective P-gp function may devaluate its 
neuroprotective  potential  in  neurodegenerative  disease.  So 
far, the discrepant findings relating to the effect of COX-2 
inhibition  preclude  the  set-up  of  clinical  trials  in  PD  and 
warrant further investigation of the roles of the COX isomers 
in neuroinflammatory and neurodegenerative processes. 
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